Connect Sign In
Drug Panel 9, Urine - Screen with Reflex to Confirmation/Quantitation
Ordering Recommendation
Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out drug exposure. This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
New York DOH Approval Status
Specimen Required
Random urine.
Transfer 8 mL urine with no additives or preservatives to ARUP Standard Transport Tubes. (Min: 4 mL)
Refrigerated.
Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 month
Methodology
Qualitative Enzyme Multiplied Immunoassay Technique (EMIT)/Quantitative Gas Chromatography-Mass Spectrometry (GC-MS)/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days
Reference Interval
Interpretive Data
Flagging indicates a positive result; not that the result is abnormal.
Presumptive negative results for drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class.
For medical purposes only; not valid for forensic use.
| Drugs/Drug Classes | Screen |
|---|---|
| THC (Cannabinoids) | Methodology: Immunoassay Positive Cutoff: 50 ng/mL |
| Cocaine | Methodology: Immunoassay Positive Cutoff: 150 ng/mL |
| Opiates | Methodology: Immunoassay Positive Cutoff: 300 ng/mL |
| Oxycodone | Methodology: Immunoassay Positive Cutoff: 100 ng/mL |
| Phencyclidine | Methodology: Immunoassay Positive Cutoff: 25 ng/mL |
| Amphetamines | Methodology: Immunoassay Positive Cutoff: 300 ng/mL |
| MDMA (Ecstasy) | Methodology: Immunoassay Positive Cutoff: 500 ng/mL |
| Barbiturates | Methodology: Immunoassay Positive Cutoff: 200 ng/mL |
| Benzodiazepines | Methodology: Immunoassay Positive Cutoff: 200 ng/mL |
| Methadone | Methodology: Immunoassay Positive Cutoff: 150 ng/mL |
| Propoxyphene | Methodology: Immunoassay Positive Cutoff: 300 ng/mL |
FDA
Note
If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added to confirm result. Additional charges apply.
To order testing for individual opioids, refer to Fentanyl and Metabolite - Confirmation/Quantitation - Urine (ARUP test code 0092570), Buprenorphine and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2010092), Meperidine and Metabolite Quantitative, Urine (ARUP test code 3000248), Tramadol and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2002736). For the comprehensive panel, refer to Pain Management Drug Panel by High-Resolution Time-of-Flight Mass Spectrometry and Enzyme Immunoassay, Urine (ARUP test code 2007479).
Hotline History
CPT Codes
80307; if reflexed, add 80325; 80345; 80346; 80349; 80353; 80358; 80359; 80361; 80365; 80367; 83992 (Reflexed Alt Code: G0480 )
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0090386 | Creatinine, Urine | 2161-8 |
| 0090399 | CDASU 9 Comments | 48767-8 |
| 0092191 | Amphetamines Screen, Urine | 19261-7 |
| 0092192 | Cocaine Screen, Urine | 19359-9 |
| 0092193 | Opiates Screen, Urine | 19300-3 |
| 0092194 | Phencyclidine Screen, Urine | 19659-2 |
| 0092195 | THC (Cannabinoids) Screen, Urine | 19292-2 |
| 0092196 | Barbiturates Screen, Urine | 19270-8 |
| 0092197 | Benzodiazepines Screen, Urine | 14316-4 |
| 0092198 | Propoxyphene Screen, Urine | 19429-0 |
| 0092199 | Methadone Screen, Urine | 19550-3 |
Aliases
- Barbiturates, Urine
- Creatinine, Urine
- Marijuana, Urine
- Amphetamines, Urine
- Opiates, Urine
- Pain Management
- Propoxyphene, Urine
- Phencyclidine, Urine
- Cocaine, Urine
- CDASU 9 Comments
- Methadone, Urine
- Benzodiazepines, Urine
